Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | JAK1 | P23458 | 3/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.30 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883080 | 0.82 | POLB (0.41) | FAAHPOLBELANEGPR119 | |
| SCHEMBL29587624 | 0.82 | POLB (0.41) | FAAHPOLBELANEGPR119 | |
| SCHEMBL13425474 | 0.80 | GPR119 (0.36) | FAAHELANEGPR119MAP2K4 | |
| SCHEMBL29588107 | 0.79 | FAAH (0.33) | FAAHJAK2JAK1ELANEGPR119 | |
| SCHEMBL3099665 | 0.79 | FAAH (0.33) | FAAHJAK2JAK1ELANEGPR119 | |
| SCHEMBL3347471 | 0.75 | CHRM2 (0.43) | FAAHBCHEELANEMAP2K4 | |
| SCHEMBL29588521 | 0.75 | CHRM2 (0.43) | FAAHBCHEELANEMAP2K4 | |
| SCHEMBL30676360 | 0.74 | AAK1 (0.34) | FAAHELANE | |
| SCHEMBL1585005 | 0.74 | AAK1 (0.34) | FAAHELANE | |
| SCHEMBL15724311 | 0.72 | MAP2K4 (0.40) | FAAHELANEGPR119MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134711-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20080293664-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-11-27 | — | — | US | disclosed |
| WO-2008122534-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122534-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293664-A1 | Non-nucleoside reverse transcriptase inhibitors | XDH, REV1, RTF1 | FAAH 3385/4885JAK2 2598/4885JAK1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.